B Hampel

1.1k total citations
26 papers, 876 citations indexed

About

B Hampel is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, B Hampel has authored 26 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in B Hampel's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Cystic Fibrosis Research Advances (9 papers) and Antibiotic Resistance in Bacteria (6 papers). B Hampel is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Cystic Fibrosis Research Advances (9 papers) and Antibiotic Resistance in Bacteria (6 papers). B Hampel collaborates with scholars based in Germany, United States and United Kingdom. B Hampel's co-authors include Peter Reimnitz, R Hullmann, H. Schmidt, P. Koeppe, Jeff Alder, H. Lode, Hugh Greville, Eva Polverino, Bernd Sommerauer and Tobias Welte and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and European Respiratory Journal.

In The Last Decade

B Hampel

26 papers receiving 824 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B Hampel Germany 16 359 333 281 161 109 26 876
Daniel Haverstock United States 22 734 2.0× 408 1.2× 468 1.7× 225 1.4× 128 1.2× 39 1.5k
Heino Staß Germany 21 424 1.2× 614 1.8× 256 0.9× 280 1.7× 171 1.6× 54 1.2k
Glenn S. Tillotson United States 15 414 1.2× 283 0.8× 100 0.4× 142 0.9× 127 1.2× 38 826
Harald H. Reinhart United States 17 325 0.9× 267 0.8× 94 0.3× 263 1.6× 185 1.7× 26 880
Frédérique Delatour France 9 482 1.3× 258 0.8× 128 0.5× 84 0.5× 411 3.8× 11 1.0k
L. O. White United Kingdom 18 209 0.6× 426 1.3× 74 0.3× 217 1.3× 100 0.9× 33 749
Jan G. den Hollander Netherlands 16 473 1.3× 477 1.4× 118 0.4× 371 2.3× 289 2.7× 32 1.2k
Thomas R. Beam United States 17 401 1.1× 247 0.7× 58 0.2× 166 1.0× 167 1.5× 45 869
F. Faurisson France 13 158 0.4× 171 0.5× 173 0.6× 135 0.8× 90 0.8× 26 773
Matteo Rinaldi Italy 15 319 0.9× 308 0.9× 148 0.5× 251 1.6× 217 2.0× 78 900

Countries citing papers authored by B Hampel

Since Specialization
Citations

This map shows the geographic impact of B Hampel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Hampel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Hampel more than expected).

Fields of papers citing papers by B Hampel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Hampel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Hampel. The network helps show where B Hampel may publish in the future.

Co-authorship network of co-authors of B Hampel

This figure shows the co-authorship network connecting the top 25 collaborators of B Hampel. A scholar is included among the top collaborators of B Hampel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Hampel. B Hampel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Waele, Jan J. De, José M. Tellado, Jeff Alder, et al.. (2012). Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. International Journal of Antimicrobial Agents. 41(1). 57–64. 17 indexed citations
2.
Wilson, Robert, Tobias Welte, Eva Polverino, et al.. (2012). Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal. 41(5). 1107–1115. 160 indexed citations
3.
4.
Wilson, Robert C., Tobias Welte, Eva Polverino, et al.. (2011). Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). 1929–1929. 5 indexed citations
5.
Hampel, B, et al.. (2011). Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). p2534–p2534. 1 indexed citations
6.
Alder, Jeff, Robert C. Wilson, Tobias Welte, et al.. (2011). Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. European Respiratory Journal. 38(Suppl 55). 1930–1930. 4 indexed citations
7.
8.
Judlin, P., et al.. (2010). Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG An International Journal of Obstetrics & Gynaecology. 117(12). 1475–1484. 39 indexed citations
9.
Schaper, Nicolaas C., Matthew Dryden, P. Kujath, et al.. (2010). Efficacy of moxifloxacin in the treatment of diabetic foot infections: results of the RELIEF study. 53. 2 indexed citations
10.
Solomkin, Joseph S., et al.. (2009). Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. International Journal of Antimicrobial Agents. 34(5). 439–445. 34 indexed citations
11.
Reimnitz, Peter, et al.. (2009). Moxifloxacin for the Treatment of Patients with Complicated Intra-abdominal Infections (the AIDA Study). Journal of Chemotherapy. 21(2). 170–180. 36 indexed citations
12.
Siegert, R., P Géhanno, Paul Nikolaidis, et al.. (2000). A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respiratory Medicine. 94(4). 337–344. 71 indexed citations
13.
Hampel, B, R Hullmann, & H. Schmidt. (1997). Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. The Pediatric Infectious Disease Journal. 16(1). 127–129. 126 indexed citations
14.
Schaad, Urs B., et al.. (1997). Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. The Pediatric Infectious Disease Journal. 16(1). 106–111. 43 indexed citations
15.
16.
Claros, Marina C., Diane M. Citron, S. Hunt Gerardo, et al.. (1996). Characterization of Indole-Negative Bacteroides fragilis Group Species with Use of Polymerase Chain Reaction Fingerprinting and Resistance Profiles. Clinical Infectious Diseases. 23(Supplement_1). S66–S72. 16 indexed citations
17.
Schaefer, Hans, J Wedgwood, B Hampel, et al.. (1996). Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrobial Agents and Chemotherapy. 40(1). 29–34. 43 indexed citations
18.
Lode, H., B Hampel, Géza Bruckner, & P. Koeppe. (1989). The pharmacokinetics of sultamicillin.. PubMed. 5. 17–22. 11 indexed citations
19.
Hampel, B, H. Lode, Géza Bruckner, & P. Koeppe. (1988). Comparative Pharmacokinetics of Sulbactam/Ampicillin and Clavulanic Acid/Amoxycillin in Human Volunteers. Drugs. 35(Supplement 7). 29–33. 29 indexed citations
20.
Hampel, B, H. Lode, Jutta Wagner, & P. Koeppe. (1982). Pharmacokinetics of Cefadroxil and Cefaclor During an Eight-Day Dosage Period. Antimicrobial Agents and Chemotherapy. 22(6). 1061–1063. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Haverstock Breakdown of academic impact, for papers by Heino Staß Breakdown of academic impact, for papers by Glenn S. Tillotson Breakdown of academic impact, for papers by Harald H. Reinhart Breakdown of academic impact, for papers by Frédérique Delatour Breakdown of academic impact, for papers by L. O. White Breakdown of academic impact, for papers by Jan G. den Hollander Breakdown of academic impact, for papers by Thomas R. Beam Breakdown of academic impact, for papers by F. Faurisson Breakdown of academic impact, for papers by Matteo Rinaldi
Rankless by CCL
2026